178 related articles for article (PubMed ID: 33188747)
1. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease.
Toychiev A; Navruzov B; Pazylova D; Davis N; Badalova N; Osipova S
Acta Trop; 2021 Jan; 213():105755. PubMed ID: 33188747
[TBL] [Abstract][Full Text] [Related]
2. Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis.
Toychiev A; Abdujapparov S; Imamov A; Navruzov B; Davis N; Badalova N; Osipova S
Parasitol Res; 2018 Dec; 117(12):3715-3723. PubMed ID: 30220046
[TBL] [Abstract][Full Text] [Related]
3. Six ulcerative colitis patients with refractory symptoms co-infective with Blastocystis hominis in China.
Tai WP; Hu PJ; Wu J; Lin XC
Parasitol Res; 2011 May; 108(5):1207-10. PubMed ID: 21104272
[TBL] [Abstract][Full Text] [Related]
4. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
6. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Yamamoto T; Shimoyama T; Matsumoto K
Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
8. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
9. Low prevalence of Blastocystis sp. in active ulcerative colitis patients.
Rossen NG; Bart A; Verhaar N; van Nood E; Kootte R; de Groot PF; D'Haens GR; Ponsioen CY; van Gool T
Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):1039-44. PubMed ID: 25680316
[TBL] [Abstract][Full Text] [Related]
10. Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course.
Yamamoto-Furusho JK; Torijano-Carrera E
Digestion; 2010; 82(1):18-23. PubMed ID: 20145404
[TBL] [Abstract][Full Text] [Related]
11. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
12. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R
Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445
[TBL] [Abstract][Full Text] [Related]
13. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
14. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
15. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis.
Rossignol JF; Kabil SM; Said M; Samir H; Younis AM
Clin Gastroenterol Hepatol; 2005 Oct; 3(10):987-91. PubMed ID: 16234044
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission.
Piñero G; Mañosa M; Calafat M; Vayreda E; Cañete F; Puig M; Domènech E
Gastroenterol Hepatol; 2024; 47(6):612-619. PubMed ID: 37806344
[TBL] [Abstract][Full Text] [Related]
17. Intestinal parasite infections in a rural community of Rio de Janeiro (Brazil): Prevalence and genetic diversity of Blastocystis subtypes.
Barbosa CV; Barreto MM; Andrade RJ; Sodré F; d'Avila-Levy CM; Peralta JM; Igreja RP; de Macedo HW; Santos HLC
PLoS One; 2018; 13(3):e0193860. PubMed ID: 29522552
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of intestinal protozoa infection among school-aged children on Pemba Island, Tanzania, and effect of single-dose albendazole, nitazoxanide and albendazole-nitazoxanide.
Speich B; Marti H; Ame SM; Ali SM; Bogoch II; Utzinger J; Albonico M; Keiser J
Parasit Vectors; 2013 Jan; 6():3. PubMed ID: 23289920
[TBL] [Abstract][Full Text] [Related]
20. Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.
Jiang XE; Yang SM; Zhou XJ; Zhang Y
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):935-942. PubMed ID: 32017001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
